Fate Therapeutics, Inc. (NASDAQ: FATE) Investor Investigation Over Potential Wrongdoing Announced

Investors who purchased shares of Fate Therapeutics, Inc. (NASDAQ: FATE) and currently hold any of those NASDAQ: FATE shares have certain options and should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this investigation, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Fate Therapeutics
Affected Securities: 
NASDAQ: FATE

An investigation on behalf of investors in shares of Fate Therapeutics, Inc. (NASDAQ: FATE) was announced over potential breaches of fiduciary duties by certain officers and directors at Fate Therapeutics, Inc.

The investigation by a law firm concerns whether certain Fate Therapeutics officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.

San Diego, CA based Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Shares of Fate Therapeutics, Inc. grew from $1.48 per share in May 2016 to as high as $14.03 per share in February 2018.